Intratumoral recombinant CX3CL1 (rCX3CL1) administered with ICT at ZT18 reduced tumor volume (Fig. 5F) and improved survival (Fig. S6D) to levels comparable to ZT2 ICT treatment. Here, CX3CL1 is linked to neoplasm.